Oncogenic human papillomavirus (HPV) is a causative agent in a subgroup of head and neck carcinomas, particularly tonsillar squamous cell carcinomas (TSCC). This study was undertaken because controversial data exist on the physical status of HPV-DNA and the use of p16INK4A overexpression as surrogate HPV marker, and to examine the impact of HPV and tobacco consumption on the clinical course of TSCC. Tissue sections of 81 TSCC were analyzed by HPV 16-specific fluorescence in situ hybridization (FISH) and p16INK4A-specific immunohistochemistry. Results were correlated with clinical and demographic data. HPV 16 integration was detected by FISH as punctate signals in 33 out of 81 (41%) TSCC, 32 of which showed p16INK4A accumulation. Only 5 out of 48 HPV-negative tumors showed p16INK4A immunostaining (p < 0.0001). The presence of HPV furthermore correlates significantly with low tobacco (p = 0.002) and alcohol intake (p = 0.011), poor differentiation grade (p = 0.019), small tumor size (p = 0.024), presence of a local metastasis (p = 0.001) and a decreased (loco)regional recurrence rate (p = 0.039). Statistical analysis revealed that smoking significantly increases the risk of cancer death from TSCC and that non-smoking patients with HPV-containing TSCC show a remarkably better disease-specific survival rate. HPV 16 is integrated in 41% of TSCC and strongly correlates with p16INK4A overexpression, implicating the latter to be a reliable HPV biomarker. Patients with HPV-positive tumors show a favorable prognosis as compared to those with HPV-negative tumors, but tobacco use is the strongest prognostic indicator. These findings indicate that oncogenic processes in the tonsils of non-smokers differ from those occurring in smokers, the former being related to HPV 16 infection.

Increasing evidence suggests that human oncogenic papillomaviruses (HPVs), known to cause uterine cervical and other anogenital cancers, may also be of importance in the pathogenesis of HNSCC. The strongest association has been found for oropharyngeal carcinomas, especially tonsillar carcinomas. Sero-positive patients for HPV 16 or with a history of HPV-related anogenital cancer also show increased risk rates of developing oropharyngeal cancer. The prevalence of HPV-exhibiting HNSCC, however, varies broadly amongst several studies (2–76%) due to differences in the population, combination of histological subsites, type and number of specimens analyzed, and detection methods used.

Thus, besides determining the presence of HPV DNA it has been suggested to better define the biological association of oncogenic HPV with these tumors, e.g., by means of assessing the viral copy number per cell, the viral oncoprotein E6/E7 expression levels, perturbation of pRb-dependent cell cycle control, or the physical status of the virus (episomal or integrated). In this way, several reports have shown that HPV 16 is predominantly identified in oropharyngeal carcinomas, with a frequency of ~50–70%.

Integration of high-risk HPV DNA, such as HPV 16 DNA, into the human cellular genome is considered an important step in malignant transformation. From studies on lesions of the uterine cervix it has become clear that viral integration marks the transition from a dysplastic lesion to (micro)invasive cancer. After integration and disruption of (part of) the viral early gene E2, an upregulation of the oncoproteins E6 and E7 is detected. On the one hand the E6 protein interacts specifically with the host-cell tumor suppressor protein p53 and induces its degradation. The subsequent inability to inhibit cell growth and induce apoptosis results in genetic instability. P53 mutations are therefore not a prerequisite in HPV-related tumorigenesis, and are therefore seldomly identified. On the other hand, the E7 protein inactivates the retinoblastoma tumor suppressor protein pRb, resulting in release of the transcription factor E2F and upregulation of p14ARF and p16INK4A. In oropharyngeal and especially tonsillar carcinomas, however, the literature is controversial with respect to viral integration. Results range from virus being present only in an episomal form to 100% viral integration, with or without concurrent episomal HPV,14,24,25 Also immunohistochemical detection of p16INK4A overexpression, which has been postulated as a fast, easy and less expensive alternative for the detection of...
HPV infection in tonsillar cancer, may remain negative in cases where the gene is inactivated.\(^{17,26-28}\)

With respect to the clinical course and prognosis of HPV-related tonsillar squamous cell carcinomas (TSCC), varying observations have been reported. Some authors described a survival advantage of HPV-positive TSCC patients when compared to HPV-negative cases,\(^ {29,26-31}\) while others showed the opposite result\(^ {32}\) or could not show a difference in survival outcome.\(^ {33,34}\) In addition, it has been suggested that the clinical course of the disease might be gender-specific, since males with a HPV-positive tumor had a better prognosis than males with a HPV-negative tumor, whereas this correlation could not be detected in women.\(^ {35}\)

It has also been postulated that HPV would be more prevalent in younger patients.\(^ {35,36}\)

In our study we have analyzed a series of 81 TSCC for HPV 16 using fluorescence in situ hybridization (FISH). This technique allows the visualization of 1 copy of HPV DNA in tumor cells, and at the same time the determination of the physical status (integrated versus episomal) of the virus on basis of the nuclear staining pattern. HPV 16 detection in the tumor was also correlated with p16\(^ {\text{INK4A}}\) overexpression, in order to investigate whether or not this method is reliable to distinguish between HPV-positive and HPV-negative TSCC. Furthermore, clinico-pathological characteristics, smoking, alcohol intake and disease outcome were correlated with HPV status.

### Material and methods

#### Tumor material and patient data

The study population consisted of 81 patients with a TSCC diagnosed between 1992 and 2001. Formaldehyde-fixed, paraffin-embedded archival biopsy and resection materials from these patients were selected from the archives of the Department of Pathology, University Hospital Maastricht, The Netherlands. Information on patient gender, age, smoking and alcohol consumption, treatment modality, date and cause of death, as well as tumor site, differentiation grade and TNM classification were collected from reviews of clinical, pathological, radiological and surgical reports. Patients were classified as daily tobacco smokers (>1 cigarette, pipe, and/or cigar per day) or nonsmokers (never smoker \(n = 10\) or former smoker \(n = 2\), which are those who had stopped smoking more than 10 years before the diagnosis of TSCC). Patients were also classified as drinkers (consumption of >2 whiskey equivalents per day [1 whiskey equivalent = 10 g alcohol]) or non-drinkers (0–2 whiskey equivalents/day). All patients were treated by surgery, radiotherapy, chemotherapy or a combination irrespective of their HPV status. The study protocol was approved by the institutional ethical committee, and all of the patients gave informed consent.

When available the tissue sections were taken from the resection specimen. Otherwise biopsy material was used for examination. A series of 4-μm-thick sections was cut from the specimens for detailed histopathological reclassification on basis of hematoxylin-eosin staining (H.E.B.), including the scoring of tumor grade \(i.e.,\) well, moderately, or poorly differentiated) according to the criteria of the World Health Organization.\(^ {36}\) Furthermore, we applied FISH to identify HPV 16 infestation and immunohistochemistry to visualize p16\(^ {\text{INK4A}}\) expression.

#### Detection of HPV 16 DNA by FISH

FISH for the detection of HPV 16 was performed on 4-μm thick tissue sections as described previously.\(^ {18,21}\) Formaldehyde-fixed, paraffin-embedded sections were deparaffinized, pretreated with 85% formic acid/0.3% \( \text{H}_2\text{O}_2 \) for 20 min at room temperature, and subsequently dehydrated in an ethanol series starting with 70% ethanol containing 0.01 M HCl (acetic dehydration). After air drying, the preparations were treated with 1 M NaSCN for 10 min at 80°C, followed by acidic dehydration and digestion with 4 mg/ml pepsin (800–1,200 U/mg protein from porcine stomach mucosa; Sigma Chemical, St. Louis, MO) in 0.02 M HCl. The slides were rinsed 3 times in 0.01 M HCl, aciddically dehydrated, air dried, postfixed in 1% formaldehyde in PBS for 15 min at room temperature and dehydrated in an ethanol series starting with 70% ethanol in distilled water. The digoxigenin-labeled HPV 16 probe (Panpath, Amsterdam, The Netherlands) was applied under a coverslip at a concentration of 1 ng/ml in 60% formamide, 2× SSC, 10% dextran sulphate, and a 50× excess of carrier DNA (salmon sperm DNA). Probe and target DNA were denatured simultaneously for 5 min at 80°C prior to hybridization overnight at 37°C in a humid chamber. After hybridization the preparations were washed stringently in 50% formamide, 2× SSC, pH 7.0 at 42°C (2 times, 5 min). The digoxigenin-labeled probe was detected with peroxidiase-conjugated sheep anti-digoxigen Fab fragments (Roche, Basel, Switzerland; 1:100 dilution in 4× SSC containing 5% nonfat dry milk), followed by a tyramide signal amplification (TSA) reaction using rhodamine-labeled tyramide.\(^ {18,21,37}\) Fifty microliter rhodamine-labeled tyramide (1:500 diluted from a 1 mg/ml stock solution in ethanol) in PBS containing 0.1 M imidazole, pH 7.6, and 0.001% \( \text{H}_2\text{O}_2 \) was applied under a coverslip for 10 min at 37°C. After several slides were washed in PBS containing 0.05% Tween-20 (Janssen Chimica, Beerse, Belgium) and PBS, dehydrated in an ascending ethanol series and mounted in Vectashield (Vector Laboratories, Burlingame, USA) containing 0.2 μg/ml 4',6-diamidino-2-phenyl indole (DAPI; Sigma). Slides were evaluated under the microscope and images were recorded with the Metasystems Image Pro System (black and white CCD camera; Sandhausen, Germany) mounted on top of a Leica DM-RE fluorescence microscope equipped with DAPI and rhodamine filters.

#### Controls and evaluation of FISH results

Controls included hybridizations on (i) 70% ethanol-fixed cell suspensions and formaldehyde-fixed sections of paraffin-embedded cell pellets of human uterine cervical carcinoma cell lines with known HPV 16 copy number, \(i.e.,\) CaSkii (ATCC; CRL1550; 500 integrated HPV 16 copies), SiHa (ATCC; HTB35; 1–2 integrated HPV 16 copies) and HeLa (ATCC; CCL2; 20–50 integrated HPV 18 and no HPV 16 copies); and (ii) formaldehyde-fixed, paraffin-embedded tissue sections of human uterine cervical lesions with proven integration or episomal presence (replication) of HPV 16 genomic DNA to guarantee probe specificity, sensitivity and interpretation accuracy.\(^ {18,21}\)

### Immunohistochemical staining of p16\(^ {\text{INK4A}}\)

Immunohistochemical staining of p16\(^ {\text{INK4A}}\) on 4-μm-thick formaldehyde-fixed, paraffin-embedded tissue sections was performed as described earlier.\(^ {18}\) Sections were deparaffinized and subsequently pretreated with 2% \( \text{H}_2\text{O}_2 \) in methanol for 30 min to quench endogenous peroxidase activity. Antigen retrieval was performed by microwave heating in 0.01 M citrate buffer (pH 6.0). The monoclonal antibody E6H4 (Dako, Glostrup, Denmark) was used to detect the p16\(^ {\text{INK4A}}\) protein. After incubation with biotinylated horse anti-mouse antibody, immunohistochemical detection

---

2657 PROGNOSTIC FACTORS IN TONSILLAR CANCER PATIENTS
was performed by the avidin-biotinylated peroxidase complex (ABC) procedure (both Vectastain-Elite-ABC kit; Vector). Peroxidase activity was detected using diaminobenzidine/H₂O₂. Sections were counterstained with hematoxylin and mounted in Entellan (Merck, Darmstadt, Germany). In each analysis, negative and positive controls were included. Analysis was performed by 3 independent observers (H.C.H., M.S. and E.J.M.S.) and consensus was acquired. Levels of p16̄NK₄A expression in normal squamous epithelium are under the detection limit of immunohistochemistry. Strong nuclear and cytoplasmic p16̄NK₄A staining in >25% of tumor cells was considered as positive.18,23,27

Detection of high risk HPV DNA by PCR

Genomic DNA was extracted from 5–10 × 10⁶-thick tissue sections of a subset of 25 TSCC according to the tissue protocol of the QiAamp DNA mini kit using proteinase K (Qiagen, Westburg, Leusden, The Netherlands).18 β-Globin gene PCR was performed with all DNA samples to demonstrate that they contained sufficient DNA of adequate quality and were free of substances inhibitory to PCR (268 bp PCO4/GH20 PCR product).17 HPV 16-specific PCR was performed according to Baay et al.39 In 5 tumors that were negative for HPV 16 but positive for p16̄NK₄A, both a general primer GPR+/6+ PCR (150 bp product) and a nested PCR with degenerate primers A5/A10 (527 bp product) and A6/A8 (268 bp product) for HPV were performed.30 PCR products (5 μl) were separated on 2% agarose gels and visualized by ethidium bromide staining. For HPV typing biotinylated A6/A8-PCR products were hybridized with 37 type-specific digoxigenin-labeled oligonucleotide probes in an enzyme-immunobassay (EIA) as previously described.41

Statistical analysis

Factors associated with HPV status, including presence of p16̄NK₄A overexpression, gender, age at time of diagnosis, smoking and alcohol use, TNM status and grade of the tumors, were analyzed by cross-tabulations using the 2-tailed Fisher exact test. A p value of <0.05 was chosen for all analyses. Disease-specific and overall survival curves were calculated using the Kaplan–Meier method.42 Survival was calculated from the date of diagnosis until death or until the last date the patient was known to be alive. Patients that died of other causes than tonsillar carcinoma were considered censored observations in the disease-specific survival analyses. Disease-free survival was calculated from the date of diagnosis until the date of recurrence (local, regional or distant, whichever occurred first). Patients without recurrence were censored at the date of the last follow-up or the date of death. The statistical significance of differences between survival times was determined by the log rank test in univariate analyses38 using a significance level of p ≤ 0.05.

Multivariate analyses were performed using the Cox proportional hazards model. Variables included were HPV, smoking, alcohol consumption, and T-classification. Variables remained in the model if their P values were below 0.10. All calculations were performed by use of the SPSS Base System version 11.5.

Results

Clinico-pathologic characteristics of the study population

Table I provides demographic and clinical features of the 81 patients included in this study. Seventy-three percent of the patients were male. Patient ages ranged from 39–87 years with a mean of 58.9 years.

Data concerning smoking and alcohol intake could be obtained from 80 patients. Sixty-eight of 80 (84%) patients were smokers and 49 of 80 (61%) consumed more than 2 units of alcohol/day. Twenty-three (28%) of the 80 patients consumed only tobacco, 4 (5%) only alcohol and 45 (56%) used both tobacco and alcohol, while there were only 8 (10%) patients without intoxication of alcohol or tobacco.

At time of diagnosis 40 of the 81 (49%) patients presented with a tumor <4 cm in diameter. Fifty-nine (73%) patients had lymph node metastasis at time of diagnosis, and in 22 (27%) ultrasonography and MRI could not detect a lymph node metastasis. The grade of the squamous cell carcinomas was poor or moderate in 29 (36%) patients, while the tumors were well differentiated in 49 (60%) patients.

Treatment modalities consisted of surgery, radiotherapy, chemotherapy or combinations of these (Table I). Thirty patients were never disease free, 17 (21%) patients developed a recurrent disease [12 at the primary site (local) and 5 in the neck (regional)] and 34 (42%) patients remained disease free after primary treatment. In addition, 6 patients developed a second primary tumor.

HPV 16-containing tonsillar carcinomas and correlation with p16̄NK₄A overexpression

Thirty-three (41%) out of the 81 TSCC contained punctuate, nuclear HPV 16 FISH signals in >25% of tumor cells, indicating viral integration into the cellular genome (Fig. 1a). In the other tumors no specific HPV 16 FISH signals were detected. Twenty-six of the HPV-positive tumors showed 1 integration site per nucleus, while the remaining tumors harbored either 2 integration sites per nucleus (n = 1), or two tumor areas with, respectively, 1 and 2 integration sites per nucleus (n = 1), or tumor areas with, respectively, 1 integration site per nucleus and >1 nuclear signals varying significantly in size and intensity (termed granular FISH pattern; n = 5). In addition, 11 of the 33 HPV 16-positive tumors showed evidence for a concomitant replication of the virus in specific areas of the tumor as visualized by diffusely stained nuclei (Fig. 1b). Interestingly, 32 out of the 33 (97%) HPV-positive TSCC also exhibited strong nuclear and cytoplasmic staining for p16̄NK₄A in the tumor areas harboring cells with nuclear HPV signals (Fig. 1c and 1d). Forty-three out of the 48 (90%) HPV-negative TSCC did not show any expression of p16̄NK₄A. Thus, a highly significant correlation was found between accumulation of p16̄NK₄A and the presence of HPV 16 (p < 0.0001; Table I).

In order to validate the FISH results, a subset of 25 p16̄NK₄A-positive tumors, including 20 FISH-positive cases, was subjected to HPV 16-specific PCR analysis. PCR confirmed the presence of HPV 16 DNA in the 20 FISH-positive cases. The 5 remaining TSCC, however, also proved to be negative for 36 other genital/mucosal HPV types (data not shown).

Clinico-pathological features related to the presence of HPV 16

The male/female ratio and the age distribution in the study population were identical in the HPV-positive and HPV-negative subgroup (Table I). In contrast, statistical analysis showed a significantly lower prevalence of smoking and drinking habits in patients with HPV-positive carcinomas than in patients with HPV-negative carcinomas (p = 0.002 and 0.011, respectively). In the patients with HPV-negative carcinomas the age distribution was different between smokers and nonsmokers.

The patients with HPV-positive carcinomas presented significantly more often (p = 0.001) with complaints of a swelling in the neck caused by a lymph node metastasis as compared to the patients with HPV-negative carcinomas. However, there was no difference in the number of patients with tumor spread to the regional lymph nodes between the 2 subgroups. The primary tumor size at time of presentation was found to be significantly smaller in the HPV-positive group than in the HPV-negative group (p = 0.024), suggesting that HPV-positive tumors metastasize at a smaller size than HPV-negative tumors. The HPV-positive tumors, moreover, showed significantly more often a poor or moderate histological degree of differentiation (p = 0.019).

All patients were treated according to the same protocol and therapies did not differ significantly between the HPV-positive and HPV-negative subgroups. Patients with a HPV-negative tumor
had a significantly higher chance ($p = 0.039$) of developing recurrent disease (27%; 9 local and 4 regional recurrences) compared to patients with a HPV-positive tumor (12%; 3 local and 1 regional recurrence). Recurrent disease was seen in 17 patients, and the time of occurrence ranged from 3 to 43 months after the initial diagnosis with a mean time period of 18 months. The mean recurrence-free interval was longer in the patients with HPV-positive carcinomas than in the patients with HPV-negative carcinomas, i.e., 27 versus 16 months, respectively. Only in the HPV-negative patient group second primary tumors developed in 6 out of 48 cases (13%).

### Parameters influencing patient survival

To determine the prognostic value of the presence of HPV in tonsillar carcinomas, we analyzed both overall and disease-specific survival. Two patients died postoperatively, because of bleeding and aspiration, and were excluded from the analysis. Follow-up time ranged from 0 to 141 months, with a mean of 30 months. Fifty-three of 79 (67%) patients died due to their TSCC and 8 (10%) from unrelated causes. Using the Kaplan-Meier algorithm the 5-year overall and disease-specific survival was 34 and 38%, respectively.

| Characteristic                      | Total TSCC | HPV-positive | HPV-negative | Fisher exact, $p$ |
|-------------------------------------|------------|--------------|--------------|------------------|
| **P16$^{INK4A}$ overexpression**    |            |              |              |                  |
| Yes                                 | 37 (46)    | 32 (97)      | 5 (10)       | $<0.0001$        |
| No                                  | 44 (54)    | 1 (3)        | 43 (90)      |                  |
| **Gender**                          |            |              |              |                  |
| Male                                | 59 (73)    | 24 (73)      | 35 (73)      | NS               |
| Female                              | 22 (27)    | 9 (27)       | 13 (27)      |                  |
| **Mean age at diagnosis (y)**       | 58.9       | 59.8         | 58.2         |                  |
| **Intoxication**                    |            |              |              |                  |
| Smoking                             | 23 (28)    | 11 (33)      | 12 (25)      |                  |
| Alcohol                             | 4 (5)      | 3 (9)        | 1 (2)        |                  |
| Smoking + alcohol                   | 45 (56)    | 11 (33)      | 34 (71)      |                  |
| None                                | 8 (10)     | 7 (21)       | 1 (2)        |                  |
| Unknown                             | 1 (1)      | 1 (3)        | 0            |                  |
| **Smoking**                         |            |              |              |                  |
| Yes                                 | 68 (84)    | 22 (70)      | 46 (96)      | 0.002            |
| No                                  | 12 (15)    | 10 (30)      | 2 (4)        |                  |
| **Alcohol intake**                  |            |              |              |                  |
| Yes                                 | 49 (61)    | 14 (42)      | 35 (73)      | 0.011            |
| No                                  | 31 (38)    | 18 (58)      | 13 (27)      |                  |
| Unknown                             | 1 (1)      | 1 (3)        | 0            |                  |
| **Complaints at diagnosis**         |            |              |              |                  |
| Local                               | 56 (69)    | 15 (46)      | 41 (85)      | 0.001            |
| Metastasis                          | 20 (25)    | 14 (42)      | 6 (13)       |                  |
| Unknown                             | 5 (6)      | 4 (12)       | 1 (2)        |                  |
| **Lymph node metastasis**           |            |              |              |                  |
| Positive                            | 59 (73)    | 26 (79)      | 33 (69)      | NS               |
| Negative                            | 22 (27)    | 7 (21)       | 15 (31)      |                  |
| **T-classification**                |            |              |              |                  |
| $\geq 4$ cm (T3-4)                  | 40 (49)    | 11 (33)      | 29 (60)      | 0.024            |
| $<4$ cm (T1-2)                      | 41 (51)    | 22 (67)      | 19 (40)      |                  |
| **Tumor grade**                     |            |              |              |                  |
| Poor/moderate                       | 29 (36)    | 17 (52)      | 12 (25)      | 0.019            |
| Well                                | 49 (60)    | 15 (45)      | 34 (71)      |                  |
| Unknown                             | 3 (4)      | 1 (3)        | 2 (4)        |                  |
| **Primary therapy**                 |            |              |              |                  |
| Surgery                             | 8 (10)     | 5 (15)       | 3 (6)        |                  |
| Surgery + RT                        | 36 (44)    | 17 (52)      | 19 (40)      |                  |
| RT                                  | 23 (28)    | 8 (24)       | 15 (32)      |                  |
| CT + RT                             | 4 (5)      | 0            | 4 (8)        |                  |
| CT                                  | 3 (4)      | 2 (6)        | 1 (2)        |                  |
| Surgery + CT + RT                   | 5 (6)      | 1 (3)        | 4 (8)        |                  |
| None                                | 2 (3)      | 0            | 2 (4)        |                  |
| **Recurrent disease**               |            |              |              |                  |
| Yes                                 | 17 (21)    | 4 (12)       | 13 (27)      | 0.039            |
| No                                  | 34 (42)    | 19 (58)      | 15 (31)      |                  |
| **Never disease free**              |            |              |              |                  |
| Yes                                 | 30 (37)    | 10 (30)      | 20 (42)      |                  |
| No                                  | 75 (93)    | 33 (100)     | 42 (87)      |                  |

HPV, human papillomavirus; NS, not significant; RT, radiation therapy; CT, chemotherapy.

1Strong nuclear and cytoplasmic p16$^{INK4A}$ staining in $\geq 25\%$ of tumor cells was considered positive and in $<25\%$ of cells negative.

2Patients were classified as daily tobacco smokers ($\geq 1$ cigarette, pipe and/or cigar/day) or nonsmokers (never smoker ($n = 10$) or former smoker ($n = 2$), which are those who had stopped smoking more than 10 years before the diagnosis of TSCC).

3Patients were classified as drinkers (consumption of $>2$ whiskey equivalents per day (1 whiskey equivalent $\sim 10$ g alcohol)) or nondrinkers (0–2 whiskey equivalents per day).

4As determined by ultrasonography and MRI scanning.

5Tumor grade was scored as well-, moderately- or poorly differentiated according to the criteria of the World Health Organization.
Stratification according to HPV status revealed a significantly improved 5-year overall as well as disease-specific survival for the patients with HPV-positive tumors compared to patients with HPV-negative tumors (log rank test: \(p = 0.026\) and \(p = 0.023\), respectively; see Fig. 2a). The disease-specific survival after 5 years for patients with HPV-positive carcinomas was 55\% and 29\% for patients with HPV-negative carcinomas (Hazard Ratio (HR) = 2.3; Confidence Interval (CI) = 1.1–4.5; Table II). The disease-free survival for patients with HPV-positive and HPV-negative tumors was 73 and 48\%, respectively (log rank test: \(p = 0.038\)).

Because of the strong correlation between HPV 16 FISH status and p16INK4A overexpression, the disease-specific survival curve stratified according to p16INK4A status is comparable with the stratification according to HPV 16 status (log rank test: \(p = 0.010\) and \(p = 0.023\), respectively; compare Figures 2a and 2b).

Apart from absence of HPV 16, other factors were found to be significantly associated with a shorter disease-specific survival in patients with TSCC in a univariate analysis. These include lack of p16INK4A overexpression (HR = 2.3; 95\% CI = 1.2–4.3), smoking (HR = 6.0; 95\% CI = 1.5–25; see Fig. 2c), a combination of smoking and alcohol abuse (HR = 2.8; 95\% CI = 1–7.7), a tumor diameter of \(\geq 4\) cm (HR = 2.8; 95\% CI = 1.5–5.3), and development of recurrent disease (HR = 15.2; 95\% CI = 4.2–54.6) (Table II). Gender, age, complaints at time of diagnosis, alcohol intake, lymph node status and tumor grade were not significantly related to disease-specific survival. Because tobacco use turned out to be the strongest individual predictor for an unfavorable prognosis, we also analyzed the predictive value of the HPV 16 status for survival in smokers, and of tobacco use in the patients with HPV-positive TSCC. Interestingly, HPV 16 status had no significant effect on outcome in smokers (Fig. 2d). However, 10 of the 12 nonsmokers also harbored HPV 16, and these patients had a significantly more favorable disease-specific survival than smokers with HPV-positive TSCC (Fig. 2e). In addition, HPV-positive tumors of nonsmokers were significantly smaller and less well differentiated than those of smokers (\(p = 0.026\) and 0.013, respectively; data not shown).

Using multivariate analysis (Table III), patients with HPV-negative TSCCs were found to exhibit a 2 times higher chance of cancer death (95\% CI = 0.9–4.2) compared to patients with HPV-positive tumors. Smokers had an even higher risk (5.5-fold) (95\% CI = 1.3–23.6) of dying from cancer compared to nonsmokers. Patients with a tumor \(\geq 4\) cm in diameter had a 2.6 times increased risk of cancer death (95\% CI = 1.4–4.9). Other factors including gender, age, lymph node metastasis and tumor grade did not significantly influence survival in multivariate analysis.

### Discussion

In the head and neck region oncogenic HPV 16 appears to be predominantly detected in lesions developing in the oropharynx, in particular the tonsillar fossa.6-8,10,12,17,18,44 In this report we have applied a highly sensitive FISH procedure to 81 TSCC, enabling HPV DNA detection up to the level of a single copy per cell nucleus, and discrimination between replicative (episomal) and integrated virus on the basis of the nuclear staining pattern. Using this approach 41\% of these tumors exhibited nuclear HPV signals indicative for viral integration into the cellular genome. These tumors furthermore demonstrated accumulation of the CDK4/6 inhibitor p16INK4A. HPV integration was also very strongly associated with specific clinico-pathological characteristics, as well as with absence of extravagant tobacco and/or alcohol consumption. Interestingly, the presence of HPV 16 proved to be a strong independent predictor of favorable outcome in these non-smokers. Tobacco use on the other hand was the most important predictor of a reduced survival rate in patients with TSCC.

**HPV 16 is integrated in TSCC**

Data concerning the physical status of HPV in TSCC are so far limited and confusing, ranging from virus being present only in
Our FISH results reveal that all HPV 16-positive tumors show integrated virus, predominantly seen as 1 punctate signal per tumor cell nucleus. In 7 HPV-positive cases tumor cells harbored 2 punctate nuclear signals or more signals of different size and intensity. The former FISH signal pattern is indicative for 2 integration sites in the cellular genome or for a pair of chromosomes with a single integration site, whereas the latter pattern most probably point to signals composed of integrated HPV DNA together with transcribed viral RNA. It is important to emphasize that RNA can

FIGURE 2 – Kaplan–Meier plots of disease-specific survival (in months after first diagnosis) of patients with TSCC. Stratification for (a) presence of integrated HPV 16 (n = 79); (b) p16INK4A accumulation (n = 79); (c) tobacco use (n = 79); (d) HPV status in smokers (n = 67); and (e) tobacco use in HPV-positive patients (n = 33). Censored values are noted with x.
contribute to the observed FISH signal,46 but that the protocol used in this study is optimal for unmasking integrated HPV DNA. Preliminary data on 2 mucosal dysplasia and 4 carcinoma in situ lesions identified adjacent to the 33 TSCC specimens also showed punctate FISH signals indicative for integrated HPV 16. Besides integration, 33% of the TSCC also contained areas with tumor cells showing diffuse nuclear staining indicative for the presence of episomal HPV. Studies on the physical status of HPV using PCR assays, such as the amplification of papillomavirus oncogene transcript (APOT) and the E2/E6 real-time PCR assay, have also shown HPV to be present predominantly in the integrated form.16,25 These and our findings support the hypothesis that transition of oncogenic HPV DNA from the episomal to the integrated form, as has been shown to be an important factor in uterine cervical tumorigenesis,19,21,47 might also be crucial for progression towards malignancy in TSCC. The finding of mainly episomal HPV 16 in TSCC by Mellin et al24 using restriction enzyme cleavage, ligation and PCR (rliPCR) is in contrast with this perspective. However, the difficulty of the rliPCR approach to produce the required extreme long PCR products that indicate viral integration in primary TSCC, as well as the presence of episomal virus in tumor parts or precursor lesions adjacent to or included in the cancer, may explain the data of these authors.

P16INK4A overexpression in TSCC is associated with HPV integration

Approximately 80% of HNSCC show inactivation of p16INK4A as a result of (epi)genetic alterations in this tumor suppressor gene,2,3,48 but in our study about half of the tonsillar carcinomas showed an overexpression of p16INK4A.16 Of the HPV 16-positive carcinomas all but one showed this overexpression, whereas only a few of the HPV 16-negative carcinomas showed accumulation of p16INK4A. This is in agreement with earlier reports on oropharyngeal...
The strong correlation between HPV 16 positivity and p16\textsuperscript{INK4A} overexpression further supports the statement that the accurate and relatively simple immunohistochemical detection of p16\textsuperscript{INK4A} is a good marker to identify HPV-positive lesions in tonsillar carcinogenesis and may be used in routine practice. The finding of p16\textsuperscript{INK4A} overexpression in HPV-negative tumors may be the result of oncogene-driven cellular senescence or infection with other viruses that downregulate pRB.

HPV integration correlates with poor tumor differentiation grade and metastatic progression at relatively small tumor size

In our study, the presence of tumor-associated HPV significantly correlated with a poor tumor differentiation grade, which is in agreement with other studies. HPV-negative carcinomas more often showed to be well differentiated and keratinizing, which was very significantly associated with tobacco use (p = 0.007). Whether or not this keratinization process induced by smoking might have a protective effect on HPV infection in, e.g., the oropharynx is unclear. Patients with HPV 16-positive tumors presented significantly more often with the initial complaint of a swelling in the neck. This is rather surprising since both HPV-positive and -negative tumors showed comparable percentages of detected lymph node metastases. An explanation for this different presentation might be the significantly smaller primary tumor size (p = 0.024) at the time of diagnosis, leading to less local problems in the HPV-positive patients. Another explanation may be better health awareness in patients with HPV 16-positive tumors as reflected in significantly less alcohol and tobacco abuse. The significantly smaller HPV-positive tumors were accompanied by slightly more regional metastases compared to the HPV-negative tumors, which might suggest that HPV-positive tumors have a tendency to metastasize early.

Non-smokers exhibit a markedly improved survival rate in HPV-associated TSCC

We found that patients with HPV 16-positive tumors had a significantly better disease-specific and overall survival compared to patients with HPV 16-negative tumors, which is in accordance with most recent studies focusing on oropharyngeal carcinomas and oncogenic HPV types. It has been suggested that this better survival outcome might result from a better response to radiation therapy, as a result of induction of apoptosis by intact p53, as well as from a much lower chance of developing a secondary primary tumor, because patients with HPV-positive tumors show often low or no tobacco and alcohol intake and HPV infection tends to be focal. Our data are in agreement with these suggestions, because we noticed a significantly lower tobacco and alcohol intake as well as a lower percentage of (locoregional) recurrences in HPV-positive tumor patients, and found only second primary tumor development in the HPV-negative patient group.

Our analyses also showed a significant correlation between p16\textsuperscript{INK4A} overexpression, less or absent smoking, with or without alcohol intake, tumor size < 4 cm, and less recurrent disease on the one hand, and prolonged survival on the other. Because these factors are also significantly correlated to HPV 16 positivity, they could artificially influence the survival data of the HPV 16-positive patients. Multivariate analyses adjusting for HPV, smoking, alcohol consumption and tumor size showed that smoking and tumor size were the most important factors determining survival outcome in the present study population. After these adjustments, HPV 16 positivity showed a strong tendency towards a better prognosis. Because of the relatively small study size and small number of patients in the subcategories of some of the covariates included in the multivariate analysis, additional studies are needed to confirm our results. Unlike earlier reports, we show that gender, age, alcohol consumption and lymph node status do not influence survival outcome. The latter parameter has also been found an unreliable prognostic indicator by others, which most probably is due to a higher percentage of HPV-positive, non-smoking patients with a better survival in the lymph node-positive group.

From our study we conclude that (i) HPV 16 integration is present in ~40% of TSCC, (ii) p16\textsuperscript{INK4A} immunostaining is significantly associated with HPV-positive TSCC and may function as a surrogate marker for HPV detection, (iii) the presence of HPV in TSCC correlates significantly with low amounts of tobacco and alcohol intake, poor differentiation grade, small tumor size, presence of a swelling in the neck due to local metastases and a decreased recurrence rate, and (iv) particularly non-smoking patients with HPV-containing TSCC show a remarkably better disease-specific survival rate. These data are of diagnostic and therapeutic importance, since interventions are dependent on clinical outcome parameters, and an improved understanding of the role of HPV in the carcinogenesis of TSCC may offer strategies for disease prevention.

Acknowledgements

The authors thank Dr. J.P. Klussmann (Department of Otorhinolaryngology and Head and Neck Surgery, University of Cologne, Germany) and Dr. S.J. Weissborn (Institute for Virology, University of Cologne, Germany) for helpful suggestions, and Ms. S.M.H. Claessen (Department of Molecular Cell Biology, University of Maastricht, The Netherlands) for outstanding technical support.

References

1. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of eighteen major cancers in 1985. Int J Cancer 1993;54:494-606.
2. Forastiere A, Koch W, Trotti A, Sidransky D. Head and neck cancer. N Engl J Med 2001;345:1890-900.
3. Mao L, Hong WK, Papadimitrakopoulou. Focus on head and neck cancer. Cancer Cell 2004;5:311–16.
4. Frisch M, Hjalgrim H, Jaeger AB, Biggar RJ. Changing patterns of tonsillar squamous cell carcinoma in the United States. Cancer Causes Control 2000;11:489-95.
5. Hafkamp HC, Manni JJ, Speel EJ. Role of human papillomavirus in the development of head and neck squamous cell carcinomas. Acta Otolaryngol 2004;124:520–6.
6. Paz IB, Cook N, Odom-Maryon T, Xie Y, Wilczynski SP. Human papillomavirus (HPV) in head and neck cancer. An association of HPV 16 with squamous cell carcinoma of Waldeyer’s tonsillar ring. Cancer 1997;79:595-604.
7. McKaig RG, Baric RS, Osfhan AF. Human papillomavirus and head and neck cancer: Epidemiology and molecular biology. Head Neck 1998;20:250–65.
8. Gillison ML, Koch WM, Capone RB, Spafford M, Westra WH, Wu L, Zahirak ML, Daniel RW, Vigilone M, Syner DE, Shah KV, Sidransky D. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 2000;92:709–720.
9. van Houten VM, Snijders PJ, van den Brekel MW, Kummer JA, Meijer CJ, van Leeuwen B, Denkers F, Smelee LE, Snow GB, Brakehoff RH. Biological evidence that human papillomaviruses are etiologically involved in a subgroup of head and neck squamous cell carcinomas. Int J Cancer 2001;93:252-5.
10. Snijders PJ, Cromme FV, van den Brule AJ, Schrijnenmakers HF, Snow GB, Meijer CJ, Walboomers JM. Prevalence and expression of human papillomavirus in tonsillar carcinomas, indicating a possible viral etiology. Int J Cancer 1992;51:845–850.
11. Schwartz SM, Daling JR, Doody DR, Wipf GC, Carter JJ, Madeleine MM, Mao L, Fitzgibbons ED, Huang S, Beckmann AM, McDougal JK, Galloway GK. Oral cancer risk in relation to sexual history and evidence of human papillomavirus infection. J Natl Cancer Inst 1998;90:1626–36.
12. Mork J, Lie AK, Flattke E, Hallmans G, Jellum E, Koskela P, Moller B, Pukkala E, Schiller JT, Youngman L, Lehtinen M, Dillner J. Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck. N Engl J Med 2001;344:1125–31.
13. Frisch M, Biggar RJ. Aetiological parallel between tonsillar and oropharyngeal squamous-cell carcinomas. Lancet 1999;354:1442–3.
14. Franceschi S, Munoz N, Bosch FX, Snijders PJ, Walboomers JM. Human papillomavirus and cancers of the upper aerodigestive tract: a review of epidemiological and experimental evidence. Cancer Epidemiol Biomarkers Prev 1996;5:567–75.

15. Franceschi S, Munoz N, Snijders PJ. How strong and how wide is the link between HPV and oropharyngeal cancer? Lancet 2000;356:871–2.

16. Wiest T, Schwarz E, Enders C, Pfredeierlacher, C, Bosch FX. Involvement of intact HPV16 E6/E7 gene expression in head and neck cancers with unaltered p53 status and perturbed pRB cell cycle control. Oncogene 2002;21:1510–17.

17. Klussmann JP, Weisenborn SJ, Ueland L, Dries V, Kolligs J, Jungeheuing M, Ecke HE, Dienes HP, Pfister HJ, Fuchs PG. Prevalence, distribution, and viral load of human papillomavirus 16 DNA in tonsillar carcinomas. Cancer 2001;92:2873–84.

18. Haafcamp FC, Speel EJ, Haas-Johnson M, Boletini V. A subset of head and neck squamous cell carcinomas exhibits integration of HPV 16/18 DNA and overexpression of p16INK4A and p53 in the absence of mutations in p53 exons 5-8. Int J Cancer 2003;107:394–400.

19. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002;2:342–50.

20. Ziegert C, Wulfsen N, Vinokurova S, Kissilov F, Einenkel J, Hoekel M, van Knebel Doberitz M. A comprehensive analysis of HPV integration loci in anogenital lesions combining transcript and genome-based amplification techniques. Oncogene 2003;22:3977–84.

21. Hopman AH, Snedds F, Dingel G, Ummel M, Sonke G, Molaro M, Voois JP, Speel EJ, Ramakers FC. Transition of high-grade cervical intraepithelial neoplasia to micro-invasive carcinoma is characterized by integration of HPV 16/18 and numerical chromosome abnormalities. PLoS Pathog 2006;2:23–34.

22. Menger K, Scheffner M, Huibrechts E, Howley PM. Interactions of HPV E6 and E7 oncoproteins with tumour suppressor gene products. Cancer Surv 2002;36:197–217.

23. Klaas R, Benner A, Friedrich T, Ridder R, Herrington CS. HPV oncoproteins biological activity in head and neck cancer. Proc AACR 2004;45:427–28 (abstract 1862).

24. Keller S, Knobloch A, Fritzsch A, Pfister HJ, Dienes H, Eckel HE, Fuchs PG. Prevalence of p16 (INK4A) as a marker for dysplastic and neoplastic cervical cells in the cervix uteri. Int J Cancer 2001;92:276–84.

25. Mellin H, Dahlgren L, Munck-Wikland E, Lindholm J, Rabbani H, Klaes R, Friedrich T, Spitkovsky D, Ridder R, Rudy W, Petry U, Dienes H, Eckel HE, Fuchs PG. Prevalence of p16 (INK4A) as a marker for dysplastic and neoplastic cervical cells in the cervix uteri. Int J Cancer 2001;92:276–84.

26. Messing R, Gehlert D, Kamb D, Sidransky D, Westra WH. BRAF V600E-associated senescence-like cell cycle arrest of human papillomavirus-infected cells. Cancer Res 2006;66:736–47.

27. Ritchie JM, Smith EM, Summersgill KF, Hoffman HT, Wang D, Klussmann JP, Turek LP, Haugen TH. Human papillomavirus infection as a prognostic factor in carcinomas of the oral cavity and oro-pharynx. Int J Cancer 2003;107:401–6.

28. Ziegert C, Wulfsen N, Vinokurova S, Kissilov F, Einenkel J, Hoekel M, van Knebel Doberitz M. A comprehensive analysis of HPV integration loci in anogenital lesions combining transcript and genome-based amplification techniques. Oncogene 2003;22:3977–84.

29. Klussmann JP, Turek LP, Haugen TH. Human papillomavirus infection and survival in oral squamous cell cancer: a population-based study. Otolaryngol Head Neck Surg 2001;125:1–9.

30. Friesland S, Fernberg JO, Lundell G, Munck-Wikland E, Strander H, Al-Abdulwahed S, Kudryk W, Al-Rajhi N. Carcinoma of the tonsil: a molecular analysis of HPV associations. Head Neck Oncol 2004;6:36–47.

31. Ahrendt S, Eby Y, Sewell D, Navroz H, Bartek J, Sidransky D. High frequency of p16 (CDKN2A/MTS1) inactivation in head and neck squamous cell carcinoma. Cancer Res 1996;56:3630–3.

32. Weinberger PM, Yu ZY, Hafty BG, Kowalski D, Harigopal M, Brandsma D, Sasaki C, Joe J, Camp RL, Rimm DL, Psyrris A. Molecular classification identifies a subset of human papillomavirus-associated oropharyngeal cancers with favorable prognosis. J Clin Oncol 2006;24:736–47.

33. Michaloglou C, Vredeveeld LCW, Soengas MS, Denolle C, Uitlman T, van der Horst CM, Majoor DM, Shuy JW, Mooi JW, Peper DS. BRAP V600E-associated senescence-like cell cycle arrest of human naevi. Nature 2005;436:720–4.

34. Castillo JP, Kowalik TF. Human cytomegalovirus infection as a potential risk factor for the development of tonsillar squamous cell carcinoma. Cancer Gene Ther 2002;9:296–300.

35. Helt A-M, Galloway DA. Mechanisms by which DNA tumor virus oncoproteins target Rb family of pocket proteins. Carcinogenesis 2003;24:159–69.

36. Wilczynski SP, Lin BT, Xie Y, Paz IB. Detection of human papillomavirus DNA and oncoprotein overexpression are associated with distinct morphological patterns of tonsillar squamous cell carcinoma. Am J Pathol 1998;152:15–26.

37. Li W, Thompson CH, O'Brien CJ, McNiel EB, Scolyer RA, Cossart MP, Stoltz E, Herbrink P. Comprehensive study of several genetic and type-specific primer pairs for detection of human papillomavirus DNA by PCR in paraffin-embedded cervical carcinomas. J Clin Microbiol 1996;34:745–7.

38. Friesland S, Fernberg JO, Lundell G, Munck-Wikland E, Strander H, Lewensohn R. Prognostic impact of complete remission after preoperative irradiation of tonsillar carcinoma: a retrospective analysis of the radiumhemmet data, 1980-1995. Int J Radiat Oncol Biol Phys 1999;45:1259–66.